商品编号


AG-40B-0041-5010



品牌


Adipogen



公司


Adipogen



公司分类


Proteins



Size

5 x 10 ?g


商品信息


More Information



Product Details



Synonyms

Interleukin-33; IL-1F11; NF-HEV



Product Type

Protein



Properties



Source/Host

E. coli



Sequence

Mouse IL-33 (aa 109-266) is untagged.



Crossreactivity

Human
Mouse



Specificity

Binds to mouse and human ST2.



BIOLOG
ical Activity

Activates ST2-dependent NF-κB pathway.



MW

~18kDa



Purity

≥95% (SDS-PAGE)



Endotoxin Content

<0.1eu mu;g="" purified="" protein="" (lal="" test;="" lonza).="">0.1eu>



Concentration

0.1mg/ml after reconstitution.



Reconstitution

Reconstitute with 100μl sterile water.



Formulation

Lyophilized. Contains PBS.



Other Product Data

UniProt link Q2YEJ4: Interleukin-33 (mouse)



Shipping and Handling



Shipping

BLUE ICE



Short Term Storage

+4°C



Long Term Storage

-20°C



Handling Advice

After reconstitution, prepare aliquots and store at -20°C.
Avoid freeze/thaw cycles.
PBS containing at least 0.1% BSA should be used for further dilutions.



Use/St
ABI
lity

Stable for at least 6 months after receipt when stored at -20°C.



Documents



MSD
S


Download PDF



Product Specification Sheet



Datasheet


Download PDF





Interleukin-33 (IL-33; HF-NEV; IL-1F11), a member of the IL-1 family of cytokines, is expressed by many cell types following pro-inflammatory stimulation and is thought to be released upon cell lysis. IL33 binds to and signals through ST2 (IL1R1) and its stimulation recruits MYD88, IRAK, IRAK4, and TRAF6, followed by phosphorylation of ERK1(MAPK3)/ERK2(MAPK1), p38(MAPK14), and JNK. The
ABI
lity of IL-33 to target numerous immune cell types, like Th2-like cells, mast cells, and B1 cells, and to induce cytokine and chemokine production underlines its potential in influencing the outcome of a wide range of diseases, such as arthritis, asthma, atopic allergy & anaphylaxis, cardiovascular disease/atherosclerosis, nervous system diseases, and sepsis.


Product References

Regulation of de novo
ADI
pocyte differentiation through crosstalk between
ADI
pocytes and pre-
ADI
pocytes: T.D. Challa, et al.; Diabetes
64,
4075 (2015)